2024
RNA-Seq based gene expression profiling of baseline and on-treatment breast tumors to predict response to HER2-directed therapy, without chemotherapy (TBCRC026).
Hennessy M, Fernández A, Huang C, Cimino-Mathews A, Denbow R, Abramson V, Rimawi M, Specht J, Storniolo A, Valero V, Vaklavas C, Winer E, Krop I, Wolff A, Wahl R, Thompson E, Stearns V, Perou C, Carey L, Connolly R. RNA-Seq based gene expression profiling of baseline and on-treatment breast tumors to predict response to HER2-directed therapy, without chemotherapy (TBCRC026). Journal Of Clinical Oncology 2024, 42: 530-530. DOI: 10.1200/jco.2024.42.16_suppl.530.Peer-Reviewed Original ResearchRelapse-free survivalB cell signaturesGene expression signaturesHER2-directed therapyPET/CT parametersER-negativeHER2 subtypeClinical outcomesEarly stage HER2-positive breast cancerResponse to HER2-directed therapyAssociated with lack of responseHER2-positive breast cancerGene expression changesUnivariate logistic regression analysisHER2-positive cohortIncreased immune signalingMetabolic changesAssociated with pCRNatural killer cellsNested Cox modelsLogistic regression analysisWilcoxon signed-rank testHER2 ampliconFDG-PET/CTHER2- tumors
2012
Evaluation of gene expression by RNA-seq after single dose of trastuzumab (T) reveals predictors of pathologic complete response (pCR) in HER2-positive early breast cancer.
Galanina N, Sprecher E, Bossuyt V, Sarkar S, Krop I, Winer E, Tuck D, Bruce C, Harris L. Evaluation of gene expression by RNA-seq after single dose of trastuzumab (T) reveals predictors of pathologic complete response (pCR) in HER2-positive early breast cancer. Journal Of Clinical Oncology 2012, 30: 10558-10558. DOI: 10.1200/jco.2012.30.15_suppl.10558.Peer-Reviewed Original ResearchPathologic complete responseSingle doseClinical trialsHER2-positive early breast cancerEarly breast cancer patientsEarly breast cancerBreast cancer patientsTumor core biopsiesSubsequent clinical trialsWeek time pointMost gene expression changesComplete responseCancer patientsPredictive markerCore biopsyBreast cancerImmune pathwaysTumorsTime pointsB2MGene expression changesBrief exposureHER2DoseTrials